MX2010009628A - Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos. - Google Patents
Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.Info
- Publication number
- MX2010009628A MX2010009628A MX2010009628A MX2010009628A MX2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A
- Authority
- MX
- Mexico
- Prior art keywords
- infective
- liquid formulations
- stable liquid
- dosing regimens
- adjusted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen métodos para determinar un régimen de dosificación ajustado a la resistencia, de un agente antiinfeccioso para el tratamiento de una infección de un mamífero por un organismo infeccioso resistente, en donde se conoce un régimen de dosificación efectivo del agente antiinfeccioso para el tratamiento de una infección del mamífero por una cepa susceptible del organismo infeccioso; se proveen también métodos de tratamiento de una infección bacteriana resistente a cefepima en un paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3359808P | 2008-03-04 | 2008-03-04 | |
PCT/US2009/035794 WO2009111422A2 (en) | 2008-03-04 | 2009-03-03 | Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010009628A true MX2010009628A (es) | 2010-09-28 |
Family
ID=41054292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010009628A MX2010009628A (es) | 2008-03-04 | 2009-03-03 | Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US20090227554A1 (es) |
EP (1) | EP2257159A4 (es) |
JP (1) | JP2011514902A (es) |
KR (1) | KR20100137439A (es) |
AU (1) | AU2009222020A1 (es) |
CA (1) | CA2713989A1 (es) |
IL (1) | IL207968A0 (es) |
MX (1) | MX2010009628A (es) |
NO (1) | NO20101375L (es) |
TW (1) | TW200940552A (es) |
WO (1) | WO2009111422A2 (es) |
ZA (1) | ZA201005495B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9120795B2 (en) | 2013-03-14 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | Crystalline form of a β-lactamase inhibitor |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
MX2020004205A (es) * | 2013-03-15 | 2021-11-16 | Merck Sharp & Dohme Llc | Composiciones antibioticas de ceftolozano. |
US20140274991A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
EP3043797B1 (en) | 2013-09-09 | 2020-04-08 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US20150094293A1 (en) | 2013-09-27 | 2015-04-02 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
US20180064723A1 (en) * | 2016-03-31 | 2018-03-08 | Wockhardt Limited | Antibacterial compositions and methods |
MX2017013434A (es) * | 2016-03-31 | 2018-01-30 | Wockhardt Ltd | Composiciones antibacterianas. |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1115417B1 (en) * | 1998-09-25 | 2006-04-05 | Cubist Pharmaceuticals, Inc. | Use of daptomycin |
JP2002543434A (ja) * | 1999-04-29 | 2002-12-17 | デイド マイクロスキャン インコーポレーテッド | 迅速な抗菌物質感受性アッセイと微生物同定を組み合わせたシステム |
US6884791B2 (en) * | 1999-07-06 | 2005-04-26 | Methylgene, Inc. | Inhibitors of β-lactamase |
US6482982B1 (en) * | 2001-03-09 | 2002-11-19 | University Of Sciences Of Philadelphia | Halogenated antituberculosis agents |
WO2004043335A2 (en) * | 2001-09-13 | 2004-05-27 | Genesoft, Inc. | Methods of treating infection by drug resistant bacteria |
US7378408B2 (en) * | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
US20030152515A1 (en) * | 2002-02-06 | 2003-08-14 | Ren-Jin Lee | Method for estimating effective regimens and patient survival rates of antibiotic treatments for fatal infectious diseases |
AU2003242404A1 (en) * | 2002-06-13 | 2003-12-31 | Hououdou Co., Ltd. | Antibacterial agent and antibacterial composition |
AU2003241675A1 (en) * | 2002-06-21 | 2004-01-06 | Shionogi And Co., Ltd. | Medicinal cephem compound composition for injection |
US7244712B2 (en) * | 2003-03-14 | 2007-07-17 | President And Fellows Of Harvard College | Aminoglycoside antibiotics and methods of using same |
US20060018966A1 (en) * | 2003-07-22 | 2006-01-26 | Lin Victor S | Antimicrobial mesoporous silica nanoparticles |
WO2005041978A1 (en) * | 2003-10-21 | 2005-05-12 | Johns Hopkins University | Neuroprotection with beta-lactam compounds |
WO2005089738A2 (en) * | 2004-03-17 | 2005-09-29 | Mpex Pharmaceuticals, Inc. | Use and administration of bacterial efflux pump inhibitors |
WO2005094800A2 (en) * | 2004-03-31 | 2005-10-13 | Lupin Ltd. | A co-precipitated cefepime composition and process for preparation thereof |
EP1656930A1 (en) * | 2004-11-10 | 2006-05-17 | Basilea Pharmaceutica AG | Stabilized freeze-dried formulation for cephalosporin derivatives |
US20070231335A1 (en) * | 2005-07-20 | 2007-10-04 | Bruce Beutler | Compositions and methods for treating Gram positive bacterial infection in a mammalian subject |
EP3718532A1 (en) * | 2005-12-08 | 2020-10-07 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
AU2007229275B2 (en) * | 2006-03-23 | 2013-02-07 | Agriculture Victoria Services Pty Ltd | Antimicrobial protein |
US20090048160A1 (en) * | 2007-08-17 | 2009-02-19 | Bannerman Douglas D | Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis isolates |
WO2009059379A1 (en) * | 2007-11-07 | 2009-05-14 | Dynamic Microbials Limited | Antimicrobial compositions, formulations and uses thereof |
-
2009
- 2009-03-03 AU AU2009222020A patent/AU2009222020A1/en not_active Abandoned
- 2009-03-03 TW TW098106848A patent/TW200940552A/zh unknown
- 2009-03-03 KR KR1020107019625A patent/KR20100137439A/ko not_active Application Discontinuation
- 2009-03-03 EP EP09716595A patent/EP2257159A4/en not_active Withdrawn
- 2009-03-03 JP JP2010549795A patent/JP2011514902A/ja active Pending
- 2009-03-03 MX MX2010009628A patent/MX2010009628A/es not_active Application Discontinuation
- 2009-03-03 CA CA2713989A patent/CA2713989A1/en not_active Abandoned
- 2009-03-03 WO PCT/US2009/035794 patent/WO2009111422A2/en active Application Filing
- 2009-03-04 US US12/397,924 patent/US20090227554A1/en not_active Abandoned
-
2010
- 2010-08-02 ZA ZA2010/05495A patent/ZA201005495B/en unknown
- 2010-09-02 IL IL207968A patent/IL207968A0/en unknown
- 2010-10-04 NO NO20101375A patent/NO20101375L/no not_active Application Discontinuation
-
2012
- 2012-01-16 US US13/351,030 patent/US20120115836A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20120115836A1 (en) | 2012-05-10 |
EP2257159A4 (en) | 2011-05-11 |
WO2009111422A3 (en) | 2009-12-30 |
NO20101375L (no) | 2010-10-04 |
KR20100137439A (ko) | 2010-12-30 |
JP2011514902A (ja) | 2011-05-12 |
IL207968A0 (en) | 2010-12-30 |
WO2009111422A9 (en) | 2010-04-15 |
CA2713989A1 (en) | 2009-09-11 |
WO2009111422A2 (en) | 2009-09-11 |
ZA201005495B (en) | 2011-04-28 |
US20090227554A1 (en) | 2009-09-10 |
TW200940552A (en) | 2009-10-01 |
AU2009222020A1 (en) | 2009-09-11 |
EP2257159A2 (en) | 2010-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010009628A (es) | Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos. | |
TN2012000335A1 (en) | Antibody formulation and therapeutic regimens | |
MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
MX2013010770A (es) | Tratamiento de tumores solidos. | |
GEP201706786B (en) | Methods and drug products for treating alzheimer's disease | |
MX2015007714A (es) | Agente terapeutico de direccionamiento a glipicano 3 (gpc3) que es administrado a pacientes para quienes la terapia con agentes terapeuticos de direccionamiento a gpc3 es eficaz. | |
NZ717373A (en) | The use of inhibitors of bruton’s tyrosine kinase (btk) | |
MX2013005564A (es) | Medicamentos de canabinoides en bajas dosis. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
NZ701715A (en) | Means and methods for treating dlbcl | |
IN2012DN06309A (es) | ||
MX338764B (es) | Metodos de tratamiento o prevención de enfermedad asociada a influenza con soluciones acuosas con potencial de oxidación-reduccion. | |
NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
MX2009006574A (es) | Tratamiento de cancer de pulmon. | |
WO2012174224A3 (en) | Methods for administering nucleic acid-based therapeutics | |
ITFI20110166A1 (it) | Nuovi fotosensibilizzanti ad uso terapeutico. | |
NO20091580L (no) | Behandling av infant-hyperbilirubinemi ved anvendelse av lave doser stannsoporfin | |
RU2013104381A (ru) | Лечение отслойки васкуляризированного пигментного эпителия терапевтическим средством против vegf | |
UA109944U (uk) | Фармацевтична композиція для зниження рівня n-оксиду триметиламіну | |
MX358512B (es) | Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva. | |
UA99163C2 (ru) | Способ дозирования инъекционной формы палиперидона пальмитата продолжительного действия | |
TNSN06305A1 (en) | Treatment regimen for camptothecin derivatives | |
UA35047U (ru) | Способ проведения оздоровительной гимнастики | |
UA56131U (ru) | Способ применения специфического иммуноглобулина против граммотрицательных бактерий для лечения сепсиса и тяжелых инфекций | |
UA58311U (ru) | Способ дезинтоксикационной терапии при лечение собак с гнойными ранами |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |